Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 1, 2021
- Accepted in final form April 22, 2021
- First Published July 14, 2021.
Author Disclosures
- Leoni Rolfes, MD (leoni.rolfes{at}ukmuenster.de)*,
- Marc Pawlitzki, MD (marc.pawlitzki{at}ukmuenster.de)*,
- Steffen Pfeuffer, MD (steffen.pfeuffer{at}ukmuenster.de),
- Christopher Nelke, MD (christopher.nelke{at}ukmuenster.de),
- Anke Lux (anke.lux{at}med.ovgu.de),
- Refik Pul, MD (refik.pul{at}uk-essen.de),
- Christoph Kleinschnitz, MD (christoph.kleinschnitz{at}uk-essen.de),
- Konstanze Kleinschnitz, PhD (konstanzekleinschnitz{at}hotmail.com),
- Rebeca Rogall, MD (rebecca.rogall{at}gmx.de),
- Katrin Pape, MD (katrin.pape{at}unimedizin-mainz.de),
- Stefan Bittner, MD (bittner{at}uni-mainz.de),
- Frauke Zipp, MD (zipp{at}uni-mainz.de),
- Clemens Warnke, MD (clemens.warnke{at}uk-koeln.de),
- Yasemin Goereci, MD (yasemin.goereci{at}uk-koeln.de),
- Michael Schroeter, MD (michael.schroeter{at}uk-koeln.de),
- Jens Ingwersen, MD (jens.ingwersen{at}uni-duesseldorf.de),
- Orhan Aktas, MD (orhan.aktas{at}med.uni-duesseldorf.de),
- Luisa Klotz, MD (luisa.klotz{at}ukmuenster.de),
- Tobias Ruck, MD (tobias.ruck{at}med.uni-duesseldorf.de),
- Heinz Wiendl, MD (heinz.wiendl{at}ukmuenster.de) and
- Sven G. Meuth, MD
- Leoni Rolfes, MD (leoni.rolfes{at}ukmuenster.de)*,
NONE
NONE
(1) Merck Serono, travel reimbursements (2) Sanofi Genzyme, travel reimbursements
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marc Pawlitzki, MD (marc.pawlitzki{at}ukmuenster.de)*,
NONE
NONE
Novartis, funding for travel to conference 2014-2016 Merck Serono, funding for travel to conference 2017
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Steffen Pfeuffer, MD (steffen.pfeuffer{at}ukmuenster.de),
NONE
NONE
Commercial entity: Travel grants by Sanofi Genzyme, Merck, Biogen, Mylan
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Commercial entity: Research support from DIAMED and Merck Serono
NONE
NONE
Society: Research support from the German Multiple Sclerosis Society (DMSG)
NONE
NONE
NONE
NONE
NONE
NONE
- Christopher Nelke, MD (christopher.nelke{at}ukmuenster.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Nelke received research grants from the Innovative Medizinsche Forschung(IMF) Muenster.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anke Lux (anke.lux{at}med.ovgu.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Refik Pul, MD (refik.pul{at}uk-essen.de),
(1) Alexion (2) Biogen (3) Celgene (4) Merck (5) Mylan (6) Novartis (7) Roche (8) Sanofi
NONE
(1) Alexion, funding for travel to congress, speaker honoraria (2) Biogen, funding for travel to congress, speaker honararia (3) Celgene, funding for travel to congress, speaker honoraria (4) Merck, funding for travel to congress, funding for research, speaker honoraria (5) Mylan, speaker honararia (6) Novartis, funding for research, speaker honoraria (7) Roche, speaker honararia (8) Sanofi-Genzyme, speaker honoraria
Guest Editor in Frontiers in Neurology Guest Editor in Cells
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Merck (2) Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christoph Kleinschnitz, MD (christoph.kleinschnitz{at}uk-essen.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Konstanze Kleinschnitz, PhD (konstanzekleinschnitz{at}hotmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rebeca Rogall, MD (rebecca.rogall{at}gmx.de),
NONE
NONE
Merck, travel costs
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Katrin Pape, MD (katrin.pape{at}unimedizin-mainz.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stefan Bittner, MD (bittner{at}uni-mainz.de),
NONE
NONE
S. B. has received funding for travel expenses for attending meetings from Novartis and Merck Serono and honoraria from Biogen Idec, BMS, Merck Serono, Novartis, Roche, Sanofi Genzyme and TEVA.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) German Research Council (DFG, CRC-TR-128)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Frauke Zipp, MD (zipp{at}uni-mainz.de),
(1) Novartis (2) Octapharma (3) Merck Serono (4) ONO Pharma (5) Biogen (6) Genzyme (7) Celgene (8) Roche
NONE
(1) Novartis (2) Octapharma (3) Merck Serono (4) ONO Pharma (5) Biogen (6) Genzyme (7) Celgene (8) Roche
(1) Brain, Associate Editor, 2021-
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Genzyme
(1) DFG CRC-TRR 128, Co-Spokesperson/Spokesperson, 2012-2024 (2) DFG CRC1080, PI, 2013-2024 (3) BMBF HaltMS, PI, 2020-2023
NONE
(1) Progressive MS Alliance, BRAVEinMS
NONE
NONE
NONE
NONE
NONE
NONE
- Clemens Warnke, MD (clemens.warnke{at}uk-koeln.de),
Biogen, Novartis, Roche, Janssen; institutional fees only.
NONE
Speakers honoraria Novartis, Biogen, Bayer, Genzyme, Alexion. Institutional fees only.
Frontiers in Neurology, associate editor, 2016-
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Speakers honoraria payed to the institution: Novartis, Biogen, Roche.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yasemin Goereci, MD (yasemin.goereci{at}uk-koeln.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael Schroeter, MD (michael.schroeter{at}uk-koeln.de),
NONE
NONE
(1)Astellas, speaker honorarium, (2)Bayer, speaker + travel honoraria, (3) Biogen Idecspeaker + travel honoraria, (4) Merck Serono speaker + travel honoraria, ( 5)Teva, speaker + travel honoraria, (6) Novartis Pharma, speaker honoraria, (7) Sanofi, speaker + travel honoraria.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis, (2) Bayer
(1)EU FP7 program #2780006, ÂNeuroFGL
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jens Ingwersen, MD (jens.ingwersen{at}uni-duesseldorf.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Orhan Aktas, MD (orhan.aktas{at}med.uni-duesseldorf.de),
(1) Medimmune Scientific Advisory Board
NONE
(1) Bayer, speaker honoraria (2) Novartis, speaker honoraria (3) Biogen, travel and speaker honoraria (4) Merck Serono, travel and speaker honoraria (5) Teva, speaker honoraria (6) Sanofi-Genzyme, speaker honoraria (7) Roche, travel and speaker honoraria (8) Almirall, speaker honoraria (9) Alexion, travel and speaker honoraria (10) Celgene, travel and speaker honoraria
(1) PLoS ONE, Academic Editor, since 2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis
(1) German Ministry of Science (BMBF), PI for NationNMO/KKNMS (NationNMO‐PAT FKZ 01GI1602B), since 2016
(1) German Research Foundation (DFG), PI in GRK2578, since 2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luisa Klotz, MD (luisa.klotz{at}ukmuenster.de),
(1) Genzyme (2) Novartis (3) Roche (4) Merck (5) Janssen (6) Alexion
NONE
(1) Novartis, speaker honoraria and travel support (2) Merck Serono, speaker honoraria and travel support (3) Biogen, speaker honoraria and travel support (4) Roche, speaker honoraria and travel support (5) Genzyme, speaker honoraria and travel support (6) Teva, speaker honoraria and travel support (7) Janssen, speaker honoraria and travel support (8) Santhera, speaker honoraria and travel support (9) Grifols, speaker honoraria and travel support (10)Alexion, speaker honoraria and travel support (11)Bayer, speaker honoraria and travel support
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis (2) Biogen (3) Merck (4) Immunic AG
(1) (CRC) SFB TR-128 Impact of dietary factors on the gut-CNS-axis  implications for CNS autoimmunity A08, Project leader, 2020-2024 (2) (CRC) SFB 1009 ÂImmune-cell interactions with endothelial cells and pericytes at the blood-brain- barrier: mechanisms and consequences A03, Sub-project Leader, 2020-2024 (3) Interdisciplinary Centre for Clinical Research, Münster (IZKF),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tobias Ruck, MD (tobias.ruck{at}med.uni-duesseldorf.de),
TR has attended scientific advisory boards from Merck, Sanofi Aventis, Novartis, Alexion and Argenx.
NONE
TR has received honoraria from Celgene/BMS, Biogen, Roche, Sanofi Aventis, Alexion, Novartis, and Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
TR has received research support from Merck, Novartis and Sanofi Aventis.
TR has reveived funding from the German research foundation and the Federal Ministry of Education and Research - BMBF.
NONE
TR has reveived funding from the Else Kröner Fresenius Foundation.
NONE
NONE
NONE
NONE
NONE
NONE
- Heinz Wiendl, MD (heinz.wiendl{at}ukmuenster.de) and
(1) Biogen (2) Evgen (3) Genzyme (4) MedDay Pharmaceuticals (5) Merck Serono (5) Novartis (6) Roche Pharma AG (7) Sanofi-Aventis (8) UCB
NONE
(1) Alexion (2) Biogen (3) Cognomed (4) F. Hoffmann-La Roche Ltd. (5) Gemeinnützige Hertie-Stiftung (6) Merck Serono (7) Novartis (8) Roche Pharma AG (9) Sanofi-Genzyme (10) TEVA (11) WebMD Global
(1) PLOS ONE, Editorial board member, since 2013 (2) Neurotherapeutics, since 2013 (3) Recent Patents on Inflammation & Allergy Drug Discovery
NONE
NONE
NONE
(1) Abbvie (2) Actelion (3) Argenx (4) Biogen (5) EMD (3) IGES (4) Johnson & Johnson (5) Merck (6) Novartis (7) Roche (8) Sanofi-Genzyme (9) Swiss Multiple Sclerosis Society (10)UCB
NONE
NONE
NONE
(1) Biogen (2) GlaxoSmithKline GmbH (3) Roche Pharma AG (4) Sanofi-Genzyme
(1) German Ministry for Education and Research (BMBF), 01GI1601E, principal investigator, 2016-2019 (2)Interdisciplinary Centre of Clinical Research (IZKF) Muenster, principal investigator, 2015-2018 (4)PML Consortium, principal investigator, 2016-2018 (5) German Research Foundation, principal investigator,SFB 1009 TP A3 + SFB-TR CRC128 TP A09 + SFB TR CRC128 TP A10, TR CRC128 TP V, TR CRC128 TP Z02 2016- 2020
NONE
(1) Else Kröner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE ChildrenÂs Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Sven G. Meuth, MD
NONE
NONE
Sven G. Meuth received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi- Aventis, Chugai Pharma, QuintilesIMS, and Teva.
NONE
Effectivity of specific FXII/FXIIa inhibitors, especially rHA-Infestin-4, in treating neuroinflammatory diseases (WO 2013/113774 A1 und EP 2 263 110 A1) Biomarkers for diagnosis and management of neuro- immunological diseases (WO 2016/028699 A2) NR2B selective NMDA-Receptor antagonists for treatment of immune-mediated inflammatory diseases (Reference number: PCT/EP2016/069975) Detection of anti-neurochondrin autoantibody in patients with cerebellar ataxia or cerebellitis (US10,112,982B2) Diagnosis of a novel autoimmune disease (EP086120B1; US2018/0298072,A1)
NONE
NONE
NONE
NONE
NONE
NONE
SGM's research is funded by Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva
SGM's research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), German Academic Exchange Service, Interdisciplinary Center for Clinical Studies (IZKF) Muenster
NONE
SGM's research is funded by the German Foundation Neurology, Hertie Foundation, Else Kröner Fresenius Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology with Institute of Translational Neurology (L.R., M.P., S.P., C.N., L.K., H.W.), University Hospital Muenster, Germany; Institute for Biometrics and Bioinformatic (A.L.), Otto-von-Guericke University, Magdeburg, Germany; Department for Neurology (R.P., C.K., K.K., R.R.), University Hospital Essen, Germany; Focus Program Translational Neurosciences (FTN) and Immunology (FZI) (K.P., S.B., F.Z.), Rhine Main Neuroscience Network (rmn2), Department of Neurology, University Medical Center of the Johannes Gutenberg University Mainz, Germany; Department of Neurology (C.W., Y.G., M.S.), University Hospital Cologne, Germany; and Department of Neurology (J.I., O.A., T.R., S.G.M.), Heinrich-Heine University, Duesseldorf, Germany.
- Correspondence
Dr. Meuth sven.meuth{at}uni-duesseldorf.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
A New England COVID-19 Registry of Patients With CNS Demyelinating DiseaseA Pilot AnalysisKelli M. Money, Ashmanie Mahatoo, Soleil Samaan et al.Neurology: Neuroimmunology & Neuroinflammation, August 02, 2021 -
Views & Reviews
Unraveling B lymphocytes in CNS inflammatory diseasesDistinct mechanisms and treatment targetsBruna Klein da Costa, Renata Brant de Souza Melo, Giordani Rodrigues dos Passos et al.Neurology, September 09, 2020 -
Article
COVID-19 and MS disease-modifying therapiesJoseph R. Berger, Rachel Brandstadter, Amit Bar-Or et al.Neurology: Neuroimmunology & Neuroinflammation, May 15, 2020 -
Views & Reviews
Targeting B cells to modify MS, NMOSD, and MOGADPart 2Jonas Graf, Jan Mares, Michael Barnett et al.Neurology: Neuroimmunology & Neuroinflammation, December 16, 2020